{"id":"f493ea3e-f7f2-5fae-916c-69af903c76e2","stable_key":"e3f6ce02-0bd7-5103-acc1-68503ab6751b:dpn05-pain","predicate":"context_dependent_observation","statement":"Pain improved in one study and the pooled 1,000-mg-three-times-daily subgroup, rather than uniformly across both trials and doses.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"01083f51-ba3c-5d71-a0eb-5cb6c6b3b9e3","mechanism_event_label":"Pain improved in one study and the pooled 1,000-mg-three-times-daily subgroup, rather than uniformly across both trials and doses.","subject":{"id":"5ce394a9-6ec6-56dd-866f-37d85c0556e4","slug":"acetylcarnitine","display_name":"Acetyl-L-carnitine","entity_type_key":"small_molecule"},"object":{"id":"9def8263-28c5-54dd-b44a-fca738385e5b","slug":"human-dpn-pain","display_name":"Human diabetic-neuropathy pain score","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"01083f51-ba3c-5d71-a0eb-5cb6c6b3b9e3","stable_key":"e3f6ce02-0bd7-5103-acc1-68503ab6751b:dpn05-pain-event","event_type":"experimental_observation","label":"Pain improved in one study and the pooled 1,000-mg-three-times-daily subgroup, rather than uniformly across both trials and doses.","description":"### dpn05-pain\n\nPain improved in one study and the pooled 1,000-mg-three-times-daily subgroup, rather than uniformly across both trials and doses.\nPain was assessed in participants for whom it was the most bothersome symptom. This is not consistent benefit in every randomized participant.\nModel and exposure: Two 52-week placebo-controlled trials; 1,257 ITT patients; 500 or 1,000 mg three times daily.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials. | 2005 | https://pubmed.ncbi.nlm.nih.gov/15616239/ | https://doi.org/10.2337/diacare.28.1.89 | Access: Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"5ce394a9-6ec6-56dd-866f-37d85c0556e4","slug":"acetylcarnitine","display_name":"Acetyl-L-carnitine","entity_type_key":"small_molecule"},"role":"tested factor","stoichiometry":null,"state_label":"ALCAR regimen","sequence_order":0,"notes":""},{"entity":{"id":"9def8263-28c5-54dd-b44a-fca738385e5b","slug":"human-dpn-pain","display_name":"Human diabetic-neuropathy pain score","entity_type_key":"cellular_process"},"role":"measured outcome","stoichiometry":null,"state_label":"mixed","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"ALCAR regimen\", \"comparator\": \"Placebo\", \"endpoint\": \"Pain improved in one study and the pooled 1,000-mg-three-times-daily subgroup, rather than uniformly across both trials and doses.\", \"effect_direction\": \"mixed\", \"combination\": \"single\", \"conditions\": []}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; source-derived draft.","entity":null},{"dimension":"experimental_model","value_text":"Two 52-week placebo-controlled trials; 1,257 ITT patients; 500 or 1,000 mg three times daily.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Source-derived curation with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Acetyl-L-carnitine collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"acetylcarnitine","display_name":"Acetyl-L-carnitine","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Pain improved in one study and the pooled 1,000-mg-three-times-daily subgroup, rather than uniformly across both trials and doses.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials. | https://pubmed.ncbi.nlm.nih.gov/15616239/ | https://doi.org/10.2337/diacare.28.1.89","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference dpn05-pain; Pain was assessed in participants for whom it was the most bothersome symptom. This is not consistent benefit in every randomized participant.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"9263edb8-7bb3-5c8b-80ca-18a7507f1127","evidence_kind":"source_excerpt","locator":"Lines 499-505","start_line":499,"end_line":505,"excerpt":"### dpn05-pain\n\nPain improved in one study and the pooled 1,000-mg-three-times-daily subgroup, rather than uniformly across both trials and doses.\nPain was assessed in participants for whom it was the most bothersome symptom. This is not consistent benefit in every randomized participant.\nModel and exposure: Two 52-week placebo-controlled trials; 1,257 ITT patients; 500 or 1,000 mg three times daily.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials. | 2005 | https://pubmed.ncbi.nlm.nih.gov/15616239/ | https://doi.org/10.2337/diacare.28.1.89 | Access: Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","model_system":"Two 52-week placebo-controlled trials; 1,257 ITT patients; 500 or 1,000 mg three times daily.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"2588f904-245a-597a-8a12-65118013fb90","stable_key":"import-e3f6ce02-0bd7-5103-acc1-68503ab6751b","title":"Acetyl-L-carnitine: detailed mechanisms of action (reviewed 6 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original review of primary studies and clearly identified official records. Exact primary access is stated; no independent replication is claimed.","file_path":"","sha256":"84cc82d6fbb0fd5d73c4ce779e9f88e7f0184ba2d29b18ad0f153815380f2975","revision_id":"dac7a950-dbe5-5c7a-9c70-2ea711d5c71a","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}